physician-scientist Leisha A. Emens, M.D., Ph.D., has been presented with the Sy Holzer Endowed Immunotherapy Research Fund Award to advance innovative research in cancer. Internationally recognized for her work in breast cancer immunotherapy, Emens is co-leader of the Cancer Immunology and Immunotherapy Program and director of Translational Immunotherapy for the Women’s Cancer Research Center at UPMC Hillman.
Emens has developed innovative combination immunotherapies that incorporate cancer vaccines, immune checkpoint inhibitors and other immune modulators with standard and novel treatments for breast cancer. She plays a vital role in leading the effort to advance translational cancer immunotherapy at UPMC Hillman and was the first to show that a combination of immunotherapy and chemotherapy can extend the lives of women with triple negative breast cancer. Her research led to accelerated approval by the U.S. Food and Drug Administration for this treatment to address one of the
Study Suggests Way to Boost Immunotherapy Against Breast Cancer, Other Solid Tumors pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: UNC Lineberger Comprehensive Cancer Center s Jonathan S. Serody, MD, and colleagues report that adding a small molecule to a chimeric antigen receptor-T (CAR-T) cell therapy can help immune system T. view more
Credit: UNC Lineberger Comprehensive Cancer Center
CHAPEL HILL, NC Boosting immune system T cells to effectively attack solid tumors, such as breast cancers, can be done by adding a small molecule to a treatment procedure called chimeric antigen receptor-T (CAR-T) cell therapy, according to a study by researchers at the UNC Lineberger Comprehensive Cancer Center. The boost helps recruit more immune cells into battle at the tumor site. The findings are published in the